Hemotherapy for osteosarcoma Where does it come from What is it Where is it going

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 16, 2013, Pages 2183-2193

  Yamamoto, Norio ^a   Tsuchiya, Hiroyuki ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

adjuvant; chemotherapy; gene therapy; molecularly targeted therapy; neoadjuvant; osteosarcoma; survival

Indexed keywords

BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; FOLINIC ACID; IFOSFAMIDE; MELPHALAN; METHOTREXATE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURGERY; DRUG CONCENTRATION; DRUG MEGADOSE; GENE THERAPY; HUMAN; MOLECULARLY TARGETED THERAPY; OSTEOSARCOMA; REVIEW; TREATMENT RESPONSE; ADJUVANT THERAPY; BONE TUMOR; BONE NEOPLASMS;

ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; GENETIC THERAPY; HUMANS; MOLECULAR TARGETED THERAPY; NEOADJUVANT THERAPY; OSTEOSARCOMA;

EID: 84885608984     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.827171     Document Type: Review

References (96)

1. Souhami RL, Craft AW, Van der Eijken JW, et al. Randomized trial of regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet 1997;350:911-17 . An important study showing that ADM + CDDP chemotherapy is effective for osteosarcoma. (Pubitemid 27420527)
2. Zils K, Ebner F, Ott M, et al. Extraskeletal osteosarcoma of the breast in an adolescent girl. J Pediatr Hematol Oncol 2012;34:e261-3
3. Wu CZ, Li CM, Han S, et al. Extraskeletal osteosarcoma of penis: a case report. Chin J Cancer Res 2012;24:164-6
4. Dorfman HD, Czerniak B. Osteosrcoma. In: Dorfman HD, Czerniak B, editors. Bone tumors. Mosby. St. Louis: 1998. p. 128-252
5. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002;20:776-90 (Pubitemid 34111386)
6. Friedman MA, Carter SK. The therapy of osteogenic sarcoma- current status and thoughts for the future. J Surg Oncol 1972;4:482-510
7. Jaffe N. Recent advances in the chemotherapy of metastatic osteogenic sarcoma. Cancer 1972;30:1627-31
8. Jaffe N, Frei E III, Traggis D, et al. Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma. N Engl J Med 1974;291:994-7 .. A landmark study showing that chemotherapy is effective for osteosarcoma and that it can improve the survival of patients with osteosarcoma.
9. Cortes EP, Holland JF, Wang JJ, et al. Amputation and adriamycin in primary osteosarcoma. N Engl J Med 1974;291:998-1000
10. Stow WW, Gehan EA, Dyment PG, et al. Multi-drug adjuvant chemotherapy for osteosarcoma: interim report of the Southwest Oncology Group studies. Cancer Treat Rep 1978;62:265-70 . An important study showing that adjuvant multidrug chemotherapy is more effective for osteosarcoma.
11. Rosen G, Marcove RC, Caparros B, et al. Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer 1979;43:2163-77 . An important study that introduces two concepts: Preoperative chemotherapy should be added to postoperative adjuvant chemotherapy subsequent to a definitive diagnosis by biopsy; and chemotherapy should be continued until a custom prosthesis is made to reconstruct the affected limb. (Pubitemid 9246383)
12. Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 1982;49:1221-30 .. A landmark study that reports the outcomes of one of the most famous chemotherapy protocols (T-10) and advocates use of neoadjuvant chemotherapy. (Pubitemid 12187826)
13. Meyers PA, Heller G, Healey JH, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the memorial sloan-kettering osteogenic sarcoma: the memorial sloan-kettering experience. J Clin Oncol 1992;10:5-15
14. Meyers P, Gorlick R, Heller G, et al. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol 1998;16:2452-8 (Pubitemid 28309040)
15. Saeter G, Alvegard TA, Elomaa I, et al. Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent highdose methotrexate: a Scandinavian Sarcoma Group Study. J Clin Oncol 1991;9:1766-75 . A clinical study in which the dose-response relationship for HD-MTX treatment is elucidated.
16. Delepine N, Delepine G, Bacci G, et al. Influence of methotrexate dose intensity on outcome of patients with high grade osteogenic osteosarcoma. Cancer 1996;78:2127-35 (Pubitemid 26367605)
17. Provisor AJ, Ettinger LJ, Nachman JB, et al. Treatment of nenmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol 1997;15:76-84 .. A multicentre single-arm study that greatly contributed to the standardisation of chemotherapy and limb-sparing surgery in osteosarcoma treatment. (Pubitemid 27020560)
18. Ochs JJ, Freeman AI, Douglass HO. Jr, et al. Cis-dichlorodiammineplatinum (II) in advanced osteogenic sarcoma. Cancer Treat Rep 1978;62:239-45
19. Baum ES, Gaynon P, Greenberg L, et al. Phase II study of cisdichlorodiammineplatinum( II) in childhood osteosarcoma: children's Cancer Study Group Report. Cancer Treat Rep 1979;63:1621-7 (Pubitemid 10167768)
20. Ettinger LJ, Douglass HO Jr, Higby DJ, et al. Adjuvant adriamycin and cis-diamminedichloroplatinum (cisplatinum) in primary osteosarcoma. Cancer 1981;47:248-54 (Pubitemid 11179318)
21. Jaffe N, Robertson R, Ayala A, et al. Comparison of intra-arterial Cisdichlorodiammineplatinum II with high-dose methotrexate and citrovorum factor rescue in the treatment of primary osteosarcoma. J Clin oncol 1985;3:1101-4 (Pubitemid 15004831)
22. Edmonson JH, Green SJ, Ivins JC, et al. A controlled pilot study of high-dose methotrexate as postsurgical adjuvant treatment for primary osteosarcoma. J Clin Oncol 1984;2:152-6 (Pubitemid 14138401)
23. Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on release-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986;314:1600-6 (Pubitemid 16118216)
24. Eilber F, Giuliano A, Eckardt J, et al. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol 1987;5:21-6 (Pubitemid 17007852)
25. Link MP, Goorin AM, Horowitz M, et al. Adjuvant chemotherapy of high-grade osteosarcoma of the extremity: updated results of the multi-institutionalosteosarcoma study. Clin Orthop 1991;270:8-14 .. A multicentre study in which the importance of adjuvant chemotherapy for osteosarcoma is indicated.
26. Winkler K, Becker W, Kotz R, et al. Presentation of the collaborative osteosarcoma study COSS-77. Chimiother Oncol 1978;2:225-8
27. Winkler K, Beron G, Kotz R, et al. Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian Study. J Clin Oncol 1984;2:617-24 (Pubitemid 14025617)
28. Winkler K, Beron G, delling G, et al. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol 1988;6:329-37 (Pubitemid 18065939)
29. Winkler K, Bielack S, Delling G, et al. Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (Study COSS 86). Cancer 1990;66:1703-10 (Pubitemid 20381203)
30. Fuchs N, Bielack SS, Epler D, et al. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol 1998;9:893-9 (Pubitemid 28440449)
31. Bramwell VHC, Burgers M, Sneath R, et al. A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol 1992;10:1579-91 (Pubitemid 23057988)
32. Lewis IJ, Nooij MA, Whelan J, et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 2007;99:112-28
33. Marti C, Kroner T, Remagen W, et al. High-dose ifosfamide in advanced osteosarcoma. Cancer Treat Rep 1985;69:115-17 (Pubitemid 15197088)
34. Miser JS, Kinsella TJ, Triche TJ, et al. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol 1987;5:1191-8 (Pubitemid 18045304)
35. Pratt CB, Horowitz ME, Meyer WH, et al. Phase II trial of ifosfamide in children with malignant solid tumors. Cancer Treat Rep 1987;71:131-5 (Pubitemid 17030141)
36. Miser JS, Kinsella TJ, Triche TJ, et al. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol 1987;5:1191-8 (Pubitemid 18045304)
37. Bacci G, Ferrari S, Bertoni F, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Istituto Orthopedico Rizzoli according to the Istituto Orthopedico Rizzoli/Osteosarcoma-2 protocol: an updated report. J Clin Oncol 2000;18:4016-27 (Pubitemid 32038393)
38. Gentet JC, Brunat-Mentigny M, Demaille MC, et al. Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the French Society of Paediatric Oncology. Eur J Cancer 1997;33:232-7
39. Berrak SG, Pearson M, Berberoglu S, et al. High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity. Pediatr Blood Cancer 2005;44:215-19 (Pubitemid 40209429)
40. Le Deley MC, Guinebretière JM, Gentet JC, et al. SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. Eur J Cancer 2007;43:752-61 . An important study showing that IFO + VP-16 chemotherapy is effective for osteosarcoma.
41. Harris MB, Cantor AB, Goorin AM, et al. Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group study. Med Pediatr Oncol 1995;24:87-92
42. Goorin AM, Harris MB, Bernstein M, et al. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. J Clin Oncol 2002;20:426-33 (Pubitemid 34072525)
43. Ferrari S, Smeland S, Mercuri M, et al. Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma groups. J Clin Oncol 2005;23:8845-52 (Pubitemid 46211531)
44. Iwamoto Y, Tanaka K, Isu K, et al. Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J. J Orthop Sci 2009;14:397-404
45. EURAMOS-1 study: recruitment, characteristics and initial treatment of 2000 patients with high-grade osteosarcoma. Available from: http://www.ctu.mrc. ac.uk/euramos/main-site-contentpages/images-and-documents/ASCO%202012/ EURAMOS%20ASCO%202012% 20poster-final.pdf [Access 25 April 2013] . An important study that is the largest multicentre randomised prospective trial for osteosarcoma to date.
46. Geoerger B, Chisholm J, Le Deley MC, et al. Phase II study of gemcitabine with oxapiplatin in relapsed or refractory paediatric solid malignancies: an innovative therapy for children with Cancer European Consortium Study. Eur J Cancer 2011;37:230-8
47. Duffaud F, Egerer G, Ferrari S, et al. A phase II trial of second-line pemetrexed in adult with advanced/metastatic osteosarcoma. Eur J Cancer 2012;48:564-70
48. Ebb D, Meyers P, Grier H, et al. Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group. J Clin Oncol 2012;30:2545-51
49. Malempati S, Weigel B, Ingle AM, et al. Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol 2012;30:256-62
50. van Maldegem AM, Bhosale A, Gelderblom HJ, et al. Comprehensive analysis of published phase I/II clinical trials between 1990-2010 in osteosarcoma and Ewing sarcoma confirms limited outcomes and need fortranslational investment. Clin Sarcoma Res 2012;2:5
51. Tsuchiya H, Tomita K, Mori Y, et al. Caffeine-assisted chemotherapy and minimized tumor excision for nonmetastatic osteosarcoma. Anticancer Res 1998;18:657-66 . An important study indicating the capability of enhancers of anticancer drugs to achieve better clinical outcomes. (Pubitemid 28174888)
52. Yamamoto N, Tsuchiya H. Clinical observations of caffeine-potentiated chemotherapy. J Caffeine Res 2011;1:163-8
53. Tomita K, Tsuchiya H. Caffeine enhancement of the effect of anticancer agents on human sarcoma cells. Jpn J Cancer Res 1989;80:83-8 (Pubitemid 20027203)
54. Tomita K, Tsuchiya H. Enhancement of cytocidal and antitumor effect of cisplatin, by caffeine in human osteosarcoma. Clin Ther 1989;11:43-52 (Pubitemid 19112875)
55. Tsuchiya H, Tomita K, Yasutake H, et al. Growth inhibition and differentiation of murine melanoma B16-BL6 cells caused by the combination of cisplatin and caffeine. Jpn J Cancer Res 1989;80:1246-51 (Pubitemid 20050995)
56. Kyriazis AP, Kyriazis AA, Yagoda A. Enhanced therapeutic effect of cisdiamminedichloroplatinum( II) against nude mouse grown human pancreatic adenocarcinoma when combined with 1-beta-D-arabinofuranosylcytosine and caffeine. Cancer Res 1985;45:6083-7 (Pubitemid 16224763)
57. Tsai CM, Perng RP, Chen MH, et al. Greater enhancement of chemosensitivity by caffeine in high-p185neu-expressing human non-small-cell lung cancer cell lines. J Natl Cancer inst 1994;86:1018-20
58. Ogasawara H, Nishio K, Ishida T, et al. In vitro enhancement of antitumor activity of a water-soluble duocarmycin derivative, KW-2189, by caffeine-mediated DNA-repair inhibition in human lung cancer cells. Jpn J Cancer Res 1997;88:1033-7 (Pubitemid 28021474)
59. Janss AJ, Levow C, Bernhand EJ, et al. Caffeine and staurosporine enhance the cytotoxicity of cisplatin and camptothecin in human brain tumor cell lines. Exp cell Res 1998;243:29-38 (Pubitemid 28397631)
60. Takahashi M, Yanoma S, Yamamoto Y, et al. Combined effect of CDDP and caffeine against human gastric cell line in vivo. Anticancer Res 1998;18:4399-401 (Pubitemid 29043666)
61. Gorlick R. Current concepts on the molecular biology of osteosarcoma. Cancer Treat Res 2009;152:467-78
62. PosthumaDeBoer J, Witlox MA, Kaspers GJ, et al. Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature. Clin Exp Metastasis 2011;28:493-503 . An important review that explains the molecular alterations in metastatic osteosarcoma and introduces (pre)clinical studies in this field.
63. Worth LL, Jaffe N, Benjamin RS, et al. Phase II study of recombinant interleukin 1alpha and etoposide in patients with relapsed osteosarcoma. Clin Cancer Res 1997;3:1721-9 (Pubitemid 27444710)
64. Mansky PJ, Liewehr DJ, Steinberg SM, et al. Treatment of metastatic osteosarcoma with the somatostatin analog OncoLar: significant reduction of insulin-like growth factor-1 serum levels. J Pediatr Hematol Oncol 2002;24:440-6
65. Daw NC, Furman WL, Stewart CF, et al. Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol 2005;23:6172-80
66. Maki RG, Kraft AS, Scheu K, et al. A multicenter phase II study of bortezomib in recurrent or metastatic sarcomas. Cancer 2005;103:1431-8 (Pubitemid 40410740)
67. Jimeno A, Daw NC, Amador ML, et al. Analysis of biologic surrogate markers from a Children's Oncology Group Phase I trial of gefitinib in pediatric patients with solid tumors. Pediatric Blood Cancer 2007;49:352-7 (Pubitemid 47236232)
68. Kramer K, Humm JL, Souweidane MM, et al. Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8. J Clin Oncol 2007;25:5465-70 (Pubitemid 350232224)
69. Bond M, Bernstein ML, Pappo A, et al. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study. Pediatric Blood Cancer 2008;50:254-8
70. Jakacki RI, Hamilton M, Gilbertson RJ, et al. Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study. J Clin Oncol 2008;26:4921-7
71. Chawla SP, Chua VS, Fernandez L, et al. Phase I/II and phase II studies of targeted gene delivery in vivo: intravenous Rexin-G for chemotherapy- resistant sarcoma and osteosarcoma. Mol Ther 2009;17:1651-7
72. Chugh R, Wathen JK, Maki RG, et al. Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a Bayesian hierarchical statistical model. J Clin Oncol 2009;27:3148-53
73. Schuetze S, Wathen K, Choy E, et al. Results of a Sarcoma Alliance for Research through Collaboration (SARC) phase II trial of dasatinib in previously treated, high-grade, advanced sarcoma. J Clin Oncol 2010;28:10009
74. Asmane I, Watkin E, Alberti L, et al. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas. Eur J Cancer 2012;48:3027-35
75. Chawla SP, Chua VS, Fernandez L, et al. Phase I/II and phase II studies of targeted gene delivery in vivo: intravenous Rexin-G for chemotherapy- resistant sarcoma and osteosarcoma. Mol Ther 2009;17:1651-7 .. A landmark study that was the first Phase II trial of a gene therapy for osteosarcoma.
76. Waehler R, Russell SJ, Curiel DT. Engineering targeted viral vectors for gene therapy. Nat Rev Genet 2007;8:573-87 (Pubitemid 47077278)
77. Hall FL, Liu L, Zhu NL, et al. Molecular engineering of matrix-targeted retroviral vectors incorporating a surveillance function inherent in von Willebrand factor. Hum Gene Ther 2000;11:983-93 (Pubitemid 30250115)
78. Xu F, Prescott MF, Liu PX, et al. Long term inhibition of neointima formation in balloon-injured rat arteries by intraluminal instillation of a matrix-targeted retroviral vector bearing a cytocidal mutant cyclin G1 construct. Int J Mol Med 2001;8:19-30
79. Skotzko M, Wu L, Anderson WF, et al. Retroviral vector-mediated gene transfer of antisense cyclin G1 (CYCG1) inhibits proliferation of human osteogenic sarcoma cells. Cancer Res 1995;55:5493-8
80. Gordon EM, Hall FL. Rexin-G, a targeted genetic medicine for cancer. Expert Opin Biol Ther 2010;10:819-32
81. Zhou BB, Chaturvedi P, Spring K, et al. Caffeine abolishes the mammalian G(2)/M DNA damage checkpoint by inhibiting ataxia-telangiectasia-mutated kinase activity. J Biol Chem 2000;275:10342-8 (Pubitemid 30202093)
82. Sarkaria JN, Busby EC, Tibbetts RS, et al. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res 1999;59:4375-82 (Pubitemid 29418757)
83. Tibbetts RS, Brumbaugh KM, Williams JM, et al. A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev 1999;13:152-7 (Pubitemid 29061945)
84. He Z, Ma WY, Hashimoto T, et al. Induction of apoptosis by caffeine is mediated by the p53, Bax, and caspase 3 pathways. Cancer Res 2003;63:4396-401 (Pubitemid 36951009)
85. Pezzi CM, Pollock RE, Evans HL, et al. Preoperative chemotherapy for soft-tissue sarcomas of the extremities. Ann Surg 1990;211:476-81 (Pubitemid 20138190)
86. Pisters PW, Patel SR, Varma DG, et al. Preoperative chemotherapy for stage IIIB extremity soft tissue sarcoma: long-term results from a single institution. J Clin Oncol 1997;15:3481-7 (Pubitemid 27527721)
87. Meric F, Hess KR, Varma DG, et al. Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomas. Cancer 2002;95:1120-6 (Pubitemid 34925365)
88. Gortzak E, Azzarelli A, Buesa J, et al. A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. Eur J Cancer 2001;37:1096-103
89. Eilber FC, Rosen G, Eckardt J, et al. Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J Clin Oncol 2001;19:3203-9 (Pubitemid 32591437)
90. Takeuchi A, Tsuchiya H, Yamamoto N, et al. Caffeine-potentiated chemotherapy for patients with high-grade soft tissue sarcoma: long-term clinical outcome. Anticancer Res 2007;27:3489-96
91. Hayashi M, Tsuchiya H, Yamamoto N, et al. Caffeine-potentiated chemotherapy for metastatic carcinoma and lymphoma of bone and soft tissue. Anticancer Res 2005;25:2399-405 (Pubitemid 41044722)
92. Cohen M, Schoenfeld D, Wolter J. Randomized trials of chlorpromazine, caffeine, and methyl-CCNU in disseminated melanoma. Cancer Treat Rep 1980;64:151-3 (Pubitemid 10125469)
93. Stewart DJ, Hugenholtz H, Dasilva V, et al. Cytosine arabinoside plus cisplatin and other drugs as chemotherapy for gliomas. Semin Oncol 1987;14:110-15
94. Kelsen D, Hudis C, Niedzwiecki D, et al. A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma. Cancer 1991;68:965-9
95. Al-Sukhun S, Zalupski MM, Ben-Josef E, et al. Chemoradiotherapy in the treatment of regional pancreatic carcinoma: a phase II study. Am J Clin Oncol 2003;26:543-9 (Pubitemid 37523053)
96. Tsuchiya H, Tomita K, Mori Y, et al. Marginal excision for osteosarcoma with caffeine assisted chemotherapy. Clin Orthop Relat Res 1999;358:27-35 (Pubitemid 29066071)